Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Year: 2023
Type: other
Abstract: Supplemental Figure S6: In vivo efficacy of a range of doses of CLDN6-23-ADC in M202 xenograft models. ADC dosing is IV QW as indicated by the arrows
Authors: Martina S.J. McDermott, Neil A. O'Brien, Benjamin Hoffstrom, KeWei Gong, Ming Lu, Jun Zhang, Tong Luo, Min Liang, Weiping Jia, Jenny J. Hong, Kevin Chau, Simon Davenport, Bin Xie, Michael F. Press, Richard Panayiotou, Abram Handly-Santana, Joan S. Brugge, Leonard Presta, John Glaspy, Dennis J. Slamon
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4364362015